# Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026
Canonical URL: https://biopharmsignal.com/news/LUNG/pulmonx-to-report-second-quarter-2026-financial-results-on-july-29-2026-aba8edf7
Ticker: LUNG
Company: Pulmonx
Source: Pulmonx
Published: 2026-07-15 20:05 EST
Original Source URL: https://investors.pulmonx.com/news-releases/news-release-details/pulmonx-report-second-quarter-2026-financial-results-july-29
## Summary

REDWOOD CITY, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2026 after the close of trading on Wednesday,

## Article Body
REDWOOD CITY, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2026 after the close of trading on Wednesday, July 29, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/ .

About Pulmonx Corporation Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr ® Endobronchial Valve, Chartis ® Pulmonary Assessment System and StratX ® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.pulmonx.com .

Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.

Contact Brian Johnston or Webb Campbell Gilmartin Group investors@pulmonx.com
## Recent Company News
- 2026-07-15 20:05 EST — [Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026](https://biopharmsignal.com/news/LUNG/pulmonx-to-report-second-quarter-2026-financial-results-on-july-29-2026-aba8edf7) — Source: Pulmonx
- 2026-06-01 20:05 EST — [Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/LUNG/pulmonx-corporation-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Pulmonx
- 2026-04-29 20:05 EST — [Pulmonx Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/LUNG/pulmonx-reports-first-quarter-2026-financial-results) — Source: Pulmonx
- 2026-04-28 20:05 EST — [Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference](https://biopharmsignal.com/news/LUNG/pulmonx-to-present-at-the-bank-of-america-securities-2026-health-care-conference) — Source: Pulmonx
- 2026-04-15 20:05 EST — [Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026](https://biopharmsignal.com/news/LUNG/pulmonx-to-report-first-quarter-2026-financial-results-on-april-29-2026) — Source: Pulmonx
## Related News
- 2026-07-22 21:05 EST — SUPN — [Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026](https://biopharmsignal.com/news/SUPN/supernus-pharmaceuticals-to-announce-second-quarter-2026-financial-results-and-h-58b4f63d)
- 2026-07-22 20:15 EST — MOH — [Molina Healthcare Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/MOH/molina-healthcare-reports-second-quarter-2026-financial-results-343e2d32)
- 2026-07-22 20:15 EST — BFRG — [BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-the-btig-virtual-biotechnology-conference-5880a10e)
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)